Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a flu drug help stroke patients recover?

NCT ID NCT05140148

Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether amantadine, a drug already used for flu and Parkinson's, can help people recover after a stroke. Sixty adults who had an ischemic or hemorrhagic stroke will receive either amantadine or a placebo for one month. Researchers will track side effects and measure recovery using patient questionnaires over three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Amantadine
What this could lead to
If it works, this could point toward a treatment to improve recovery after a stroke.
What could go wrong
This is a small, early-phase trial with only 60 participants. The drug may not show benefit over placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18 to 85 years old, male and female 2. Modified Rankin Score (mRS)\<=2 prior to stroke 3. Ischemic or hemorrhagic stroke as diagnosed by vascular neurologist or as proven on magnetic resonance imaging (MRI) or non-contrast head computed tomography NCHCT) 4. 24 hours to 3 weeks after stroke onset or time last known well prior to detection of symptoms 5. National Institute of Health Stroke Scale (NIHSS)\>=3 and NIHSS\<=15 6. Creatinine Clearance of greater than or equal to 60 mL/min using the Cockroft- Gault equation. 7. Have passed a swallow evaluation prior to drug administration 8. The patient is an acute rehabilitation candidate or candidate for the Homeward Stroke Program 9. Able to participate in administered tests Exclusion Criteria: 1. Any degree of receptive aphasia 2. Moderate or severe expressive aphasia 3. Currently pregnant or plans to get pregnant 4. Currently breastfeeding 5. Any patient admitted with primary SubarachnoidH emorrhage (SAH )on either non-contrast head CT or MRI brain 6. Diagnosis of dementia or mild cognitive impairment prior to index stroke 7. Prior limb amputation 8. Currently prescribed or taking a primary anticholinergic medication 9. Currently enrolled in any other investigational pharmacologic or procedural clinical trial 10. Malignancy with active treatment 11. History of prior stroke with residual impairment 12. Current or prior neuroleptic use 13. History of suicidality or psychosis (The Columbia Suicide Severity Ratings Scale (C-SSRS) will be administered at the screening visit to assess depression and suicidal thoughts for subject eligibility. Any subjects who indicate severe depression or suicidal thoughts and/or attempts within the last year will not be eligible) 14. Prior history of seizures 15. Prior treatment with amantadine 16. Parkinson's disease 17. Amantadine allergy 18. Elevated liver function tests (aspartate aminotransferase and alanine aminotransferase above the upper limit of normal) -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemorrhagic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemorrhagic stroke intracerebral hemorrhage ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stroke hemorrhagic Stroke, ischemic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Hospital of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.